The Breakthrough Devices Program sounds like it lowers the bar for clearance. It doesn’t. Designation buys you FDA’s attention and a faster review once you submit — not a smaller evidence file.
What qualifying actually requires
Section 515B of the FD&C Act (21 U.S.C. § 360e-3) sets a two-part test. First, the device has to provide more effective treatment or diagnosis of a life-threatening or irreversibly debilitating disease or condition. Second, it has to meet at least one of three additional criteria: no approved or cleared alternative exists, it offers a significant advantage over existing alternatives, or its availability is in the best interest of patients. Meeting the first test alone isn’t enough — reviewers are looking for a device that clears both bars, not one.
The request is a separate submission from your marketing application, and the timing matters more than most teams expect. Request it early — ideally while you’re still shaping your pre-submission strategy — and the interaction you get back can influence your study design before it’s locked in. Request it late, after the pivotal study is already running, and you’ve traded away most of what the designation is actually for.
What the designation changes, and what it doesn’t
Once designated, you get more frequent and more senior interaction with FDA than a standard submission would see — the kind of interactive, timely communication the program is built around — along with a consistent point of contact through the review. When you eventually submit, that file gets priority review: FDA works it ahead of non-designated submissions in the same queue.
What doesn’t change is the standard your file is measured against. A 510(k) filed under breakthrough designation still needs substantial equivalence to a predicate; a De Novo or PMA still needs a reasonable assurance of safety and effectiveness, the same test any other De Novo classification order gets held to. The designation changes how much conversation you get on the way to that finding. It doesn’t change the finding itself.
Where this goes wrong
Requesting designation to rescue a submission that’s already struggling
The value of the extra interaction is almost entirely front-loaded — it shapes a study you haven’t run yet. Requested late, it mostly just adds a step.
Treating designation as a lower evidence bar
It isn’t one, and the reviewer working your file won’t treat it as one either. Build the same file you would without it.
Letting the extra FDA interaction substitute for your own regulatory strategy
It’s a channel for questions you already know you need answered — not a replacement for having a plan going in.
Breakthrough designation is worth requesting when it changes how you build the file — not when it’s a name you’re hoping will carry weight later in the review. Ask for it early, use the access it buys you to settle open questions while your study design is still a draft, and hold your file to the same standard you would have anyway. That’s what the program actually offers.
Sources & further reading
- Federal Food, Drug, and Cosmetic Act — Section 515B, Breakthrough Devices, 21 U.S.C. § 360e-3 fda.gov
- FDA — Breakthrough Devices Program fda.gov
- Regulatory Academy — What a 510(k) Actually Is — and What Clearance Means regulatoryacademy.com
- Regulatory Academy — How to Read an FDA De Novo Classification Order regulatoryacademy.com
- Regulatory Academy — How to Prepare for an FDA Pre-Submission Meeting regulatoryacademy.com
This essay is provided for general educational purposes and reflects the regulatory landscape as of its publication date. It is not legal, regulatory, or career advice.
